A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients

Journal Title: The AAPS Journal - Year 2015, Vol 17, Issue 6

Abstract

The online version of this article (doi:10.1208/s12248-015-9815-8) contains supplementary material, which is available to authorized users.

Authors and Affiliations

Ahmed Abbas Suleiman, Sebastian Frechen, Matthias Scheffler, Thomas Zander, Lucia Nogova, Martin Kocher, Ulrich Jaehde, Jürgen Wolf, Uwe Fuhr

Keywords

Related Articles

Oral bioavailability in pigs of a miconazole/Hydroxypropyl-γ-cyclodextrin/ L-tataric acid inclusion complex produced by supercritical carbon dioxide processing

The objective of this study was to determine the pharmacokinetic parameters of miconazole after oral administration of a miconazole/hydroxypropyl-γ-cyclodextrin(HPγCD)/ L-tartaric acid inclusion complex p...

Pharmacogenetic and Metabolic Differences Between Dog Breeds: Their Impact on Canine Medicine and the Use of the Dog as a Preclinical Animal Model

There is limited information describing species related pharmacogenetic differences in animals. Despite the lack of genetic information in veterinary medicine, breed specific responses to endogenous and exogenous substan...

Strategy to Prevent Drug-Related Hypersensitivity in Folate-Targeted Hapten Immunotherapy of Cancer

Cancer vaccine/immunotherapy rarely involves systemic administration of an immunogenic compound to an actively immunized host. We have developed such a strategy that utilizes folate to deliver antigenic haptens [e.g., fl...

Pharmacokinetics and Pharmacodynamics of Phenethyl Isothiocyanate: Implications in Breast Cancer Prevention

Phenethyl isothiocyanate (PEITC)—a naturally occurring isothiocyanate in cruciferous vegetables—has been extensively studied as a chemopreventive agent in several preclinical species and in humans. Pharma...

Download PDF file
  • EP ID EP681028
  • DOI  10.1208/s12248-015-9815-8
  • Views 83
  • Downloads 0

How To Cite

Ahmed Abbas Suleiman, Sebastian Frechen, Matthias Scheffler, Thomas Zander, Lucia Nogova, Martin Kocher, Ulrich Jaehde, Jürgen Wolf, Uwe Fuhr (2015). A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients. The AAPS Journal, 17(6), -. https://www.europub.co.uk/articles/-A-681028